Search results for "Kaplan-Meier"

showing 10 items of 359 documents

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

2019

Abstract Background This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. Methods 148 mRCC patients were evaluated. According to Heng score 15.5%, 60.1% and 24.4% of patients were at poor risk, intermediate and favorable risk, respectively. Results PFS, OS, DCR and ORR were 7.14 months, 15.5 months, 70.6% and 16.6%, respectively. The duration of prior sunitinib treatment correlated with a longer significant mPFS, 8.8 vs 6.3 months, respectively. Axitinib therapy was safe, without grade 4 adverse events. The most frequent toxicities of all grades were: fati…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAxitinibAxitinib; Metastatic; Renal cancer; Sunitinib; Treatmentmedicine.medical_treatmentPopulationlcsh:MedicineKaplan-Meier EstimateDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInternal medicineSunitinibHumansMedicineNeoplasm MetastasiseducationAdverse effectMetastatic renal cell cancerCarcinoma Renal CellAgedAged 80 and overSecond-line therapyeducation.field_of_studybusiness.industrySunitinibResearchlcsh:RGeneral MedicineMiddle AgedKidney NeoplasmsNephrectomyAxitinibTreatment030104 developmental biologyRenal cancer030220 oncology & carcinogenesisMultivariate AnalysisMetastaticFemalebusinessmedicine.drugJournal of Translational Medicine
researchProduct

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

2016

This analysis confirms that administering neoadjuvant chemotherapy (NACT) before chemoradiotherapy (CRT) could be a potential option for high-risk, locally advanced rectal cancer. In this setting, MRI tumour regression grade is an independent prognostic factor and, when assessed after NACT, may predict the probability and magnitude of incremental benefit from sequential CRT.EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC). We pooled individual patient data from these trials. The primary objective was overall survival (OS) in the intention-to-treat (ITT) population. Pro…

AdultMale0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentPopulationPhases of clinical researchKaplan-Meier EstimateDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProgression-free survivalStage (cooking)educationNeoadjuvant therapyAgedAged 80 and overeducation.field_of_studyIntention-to-treat analysisRectal Neoplasmsbusiness.industrySurrogate endpointChemoradiotherapyHematologyMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessChemoradiotherapy
researchProduct

Diagnosis, treatment and long-term outcomes of autoimmune pancreatitis in Spain based on the International Consensus Diagnostic Criteria: A multi-cen…

2015

Abstract Objectives Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis that has been reported worldwide for the last two decades. The aim of this study is to analyse the clinical profile of patients from Spain with AIP, as well as treatments, relapses and long-term outcomes. Methods Data from 59 patients with suspected AIP that had been diagnosed in 15 institutions are retrospectively analysed. Subjects are classified according to the International Consensus Diagnostic Criteria (ICDC). Patients with type 1 AIP (AIP1) and type 2 AIP (AIP2) are compared. Kaplan–Meier methodology is used to estimate the overall survival without relapses. Results Fifty-two patients met ICDC, 45 pat…

AdultMaleAbdominal painmedicine.medical_specialtyPathologyConsensusEndocrinology Diabetes and MetabolismKaplan-Meier EstimateDisease-Free SurvivalAutoimmune Diseases03 medical and health sciences0302 clinical medicineInternal medicinePancreatitis ChronicmedicineCombined Modality TherapyHumansPancreatitis chronicMulti centreAutoimmune pancreatitisAgedRetrospective StudiesHepatologybusiness.industryGastroenterologyRetrospective cohort studyMiddle Agedmedicine.diseaseCombined Modality TherapyTreatment OutcomeDiagnosis treatmentSpain030220 oncology & carcinogenesisPractice Guidelines as TopicPancreatitis030211 gastroenterology & hepatologyFemalemedicine.symptombusinessFollow-Up StudiesPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
researchProduct

Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.

2016

We investigated a possible interaction between age-associated risk and HLA-mismatch associated risk on prognosis in different age categories of recipients of unrelated hematopoietic stem cell transplants (HSCT) (n=3019). Patients over 55 years of age transplanted with 8/10 donors showed a mortality risk of 2.27 (CI 1.70–3.03, P<0.001) and 3.48 (CI 2.49–4.86, P<0.001) when compared to 10/10 matched patients in the same age group and to 10/10 matched patients aged 18–35 years, respectively. Compared to 10/10 matched transplantations within each age category, the Hazards Ratio for 8/10 matched transplantation was 1.14, 1.40 and 2.27 in patients aged 18–35 years, 36–55 and above 55 years. Model…

AdultMaleAdolescentmedicine.medical_treatmentAge categoriesHematopoietic stem cell transplantationHuman leukocyte antigenHistocompatibility TestingKaplan-Meier Estimate03 medical and health sciencesYoung Adult0302 clinical medicineHLA AntigensRisk FactorsCell Therapy & ImmunotherapymedicineHumansPublic Health SurveillanceYoung adultMortalityAgedbusiness.industryHistocompatibility TestingAge FactorsHematopoietic Stem Cell TransplantationHematopoietic stem cellHematologyArticlesMiddle Aged3. Good healthHistocompatibilitysurgical procedures operativemedicine.anatomical_structure030220 oncology & carcinogenesisHistocompatibilityImmunologyFemalebusinessUnrelated Donors030215 immunologyHaematologica
researchProduct

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multi…

2015

This phase 1/2 study was the first to evaluate the safety and efficacy of the cyclin-dependent kinase (CDK) 4/6-specific inhibitor palbociclib (PD-0332991) in sequential combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. The recommended phase 2 dose was palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (intravenous) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 (early G1 arrest) and days 15 and 18 (cell cycle resumed). Dose-limiting toxicities were primarily cytopenias; most other treatment-related adverse events were grade≤3. At a bortezomib dose lower than that in other combina…

AdultMaleCancer ResearchCombination therapyPyridinesKaplan-Meier EstimatePalbociclibPharmacologyDexamethasoneDrug Administration SchedulePiperazinesBortezomibRecurrenceCyclin-dependent kinaseAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineMultiple myelomaDexamethasoneAgedNeoplasm StagingAged 80 and overbiologybusiness.industryBortezomibCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HematologyMiddle AgedCell cyclemedicine.diseaseTreatment OutcomeOncologyDrug Resistance NeoplasmPharmacodynamicsRetreatmentbiology.proteinFemaleDrug MonitoringMultiple Myelomabusinessmedicine.drugLeukemia &amp; Lymphoma
researchProduct

Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular…

2013

Cholangiocellular carcinoma (CCA) is a primary hepatic malignancy derived from cholangiocytes. The prognosis for CCA patients is very poor and conventional chemotherapy has been proven ineffective in improving long‑term patient survival rates. Organic cation transporters (OCTs) mediate the transport of a broad spectrum of endogenous substrates and the detoxification of xenobiotics. Moreover, OCTs are considered responsible for the responsiveness towards platinum‑based chemotherapies. Currently, there are no data available regarding the role of OCTs in CCA. Therefore, the aim of this study was to investigate the expression of OCT1 and OCT3 in CCA and the corresponding non-neoplastic tumor‑su…

AdultMaleCancer ResearchOrganic Cation Transport ProteinsDown-RegulationKaplan-Meier EstimateBiologySLC22A3CholangiocarcinomaDownregulation and upregulationWestern blotmedicineHumansRNA MessengerAgedAged 80 and overOncogenemedicine.diagnostic_testOrganic Cation Transporter 1CancerMiddle Agedmedicine.diseaseMolecular medicineBile Ducts IntrahepaticBile Duct NeoplasmsOncologyTumor progressionDisease ProgressionCancer researchbiology.proteinImmunohistochemistryFemaleNeoplasm Recurrence LocalInternational Journal of Oncology
researchProduct

Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Ve…

2019

&lt;b&gt;&lt;i&gt;Background/Aims:&lt;/i&gt;&lt;/b&gt; Cardiovascular risk factors are not considered in the current scores for evaluation of the thrombotic risk in myeloproliferative neoplasms, and in polycythemia vera (PV) in particular. Cytoreduction is currently not indicated in low-risk patients with PV, despite the absence or presence of cardiovascular risk factors. Our purpose is to highlight how cardiovascular risk factors in patients with PV increase the thrombotic risk both in low- and high-risk patients. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; We collected and analyzed data from 165 consecutive patients with a diagnosis of PV followed at our institution and compared the fr…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationCardiovascular risk factorsKaplan-Meier EstimateSettore MED/15 - Malattie Del SangueCytoreductionYoung AdultPolycythemia veraSurvival dataInternal medicinemedicineHumansIn patienteducationAgedRetrospective StudiesAged 80 and overThrombotic riskeducation.field_of_studybusiness.industryThrombosisCytoreduction Surgical ProceduresHematologyMiddle AgedCardiovascular riskmedicine.diseaseThrombosisPolycythemia veraOncologyCardiovascular DiseasesHeart Disease Risk FactorsRisk stratificationFemalebusinessOncology Research and Treatment
researchProduct

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine : a phase 2 randomised, placebo-control…

2012

Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine.In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were sup…

AdultMaleDrug-Related Side Effects and Adverse ReactionsPyridinesPopulationMedizinAdministration OralKaplan-Meier EstimatePlacebolaw.inventionYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodPiperidinesRandomized controlled triallawHumansMedicineAdverse effecteducationAgededucation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle AgedDose-ranging studymedicine.diseaseLasmiditanSerotonin Receptor Agonists3. Good healthTreatment OutcomechemistryTolerabilityMigraine030220 oncology & carcinogenesisAnesthesiaBenzamidesFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure

2012

BACKGROUND & AIMS: Fractionated plasma separation and adsorption (FPSA) is an extracorporeal procedure that supports liver function by removing endogenous toxins that cause complications from acute-on-chronic liver failure (AOCLF). We performed a randomized trial to investigate survival of patients with AOCLF treated with FPSA. METHODS: Patients with AOCLF were randomly assigned to groups given a combination of FPSA and standard medical therapy (SMT) (FPSA group, n = 77) or only SMT (SMT group, n = 68). The Prometheus liver support system was used to provide 8 to 11 rounds of FPSA (minimum of 4 hours each) for 3 weeks. Primary end points were survival probabilities at days 28 and 90, irresp…

AdultMaleExtracorporeal Circulationmedicine.medical_specialtyTime FactorsCirrhosismedicine.medical_treatmentMedizinKaplan-Meier EstimateLiver transplantationRisk AssessmentGastroenterologyEnd Stage Liver DiseaseLIVER DISEASELiver diseaseSpontaneous bacterial peritonitisHepatorenal syndromeRisk FactorsInternal medicinemedicineHumansProspective StudiesDialysisProportional Hazards ModelsHepatologybusiness.industryMORTALITYGastroenterologyBilirubinTREATMENTLiver Failure AcuteMiddle Agedmedicine.diseaseEXTRACORPOREAL LIVER SUPPORTSurgeryEuropeTreatment OutcomeFemaleSorption DetoxificationSOFA scoreLiver functionORGAN FAILUREbusinessBiomarkers
researchProduct

Physical activity in adulthood: genes and mortality.

2015

AbstractObservational studies report a strong inverse relationship between leisure-time physical activity and all-cause mortality. Despite suggestive evidence from population-based associations, scientists have not been able to show a beneficial effect of physical activity on the risk of death in controlled intervention studies among individuals who have been healthy at baseline. On the other hand, high cardiorespiratory fitness is known to be a strong predictor of reduced mortality, even more robust than physical activity level itself. Here, in both animals and/or human twins, we show that the same genetic factors influence physical activity levels, cardiorespiratory fitness and risk of de…

AdultMaleFOOD-INTAKEPopulationPhysiologyMonozygotic twinphysical activityVOLUNTARY EXERCISEKaplan-Meier EstimateMotor ActivityBioinformaticsArticleYoung AdultGenetic PleiotropyadultsTwins DizygoticMedicineAnimalsHumansINTRINSIC AEROBIC CAPACITYYoung adultMortalityeducationta315genesFINNISH TWIN COHORTaikuisetGenetic Association StudiesALL-CAUSE MORTALITYeducation.field_of_studyMultidisciplinarygeenitbusiness.industryCardiorespiratory fitnessta3141LEISURE-TIMETwins MonozygoticTwin studymortalityPhysical activity level3142 Public health care science environmental and occupational healthRatsBODY-WEIGHTCHRONIC DISEASEObservational studyFemalebusinessCARDIORESPIRATORY FITNESSFollow-Up StudiesScientific reports
researchProduct